Ceribell anticipates revenue of $112M-$116M in 2026
Ceribell delivered revenue of $26.5 million in Q1 2026, growing 29% year-over-year and 7% sequentially.
The growth was driven by record headband utilization and the largest quarter of net new account additions.
Ceribell’s strong Q1 performance is expected to contribute to its anticipated revenue of $112M-$116M in 2026, with a target delirium NTAP of up to $2,171 per patient.